PTPN11 and lung adenocarcinoma: In this study, we generated transgenic mice expressing a PTP-defective (catalytic residues C459S/D425A mutations), dominant-negative Shp2 mutant (tetO-Shp2CSDA) to assess the effects of Shp2 PTP inhibition in a transgenic mouse model of mutant EGFR-driven lung adenocarcinoma.